Atlas Trials

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Clinical trial NCT00818649 · TERMINATED

Trial details

NCT number
NCT00818649
Sponsor
Masonic Cancer Center, University of Minnesota
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
LeukemiaMyelodysplastic Syndrome
Start date
2009-01-01
Primary completion
2012-05-01
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.